Pathway targets to explore in the treatment of small cell and large cell lung cancers

Journal of Thoracic Oncology

Volumn 4, Issue 11, 2009, Pages 1313-1321

  Paripati, Anoor ^a   Kingsley, Chris ^b   Weiss, Glen J ^a,b  

^a Scottsdale Clinical Research Institute   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Gene expression profiling; In silico; Large cell lung cancer; Pathway analysis; Small cell lung cancer; Treatment

Indexed keywords

AROMATASE INHIBITOR; BETA CATENIN; BEVACIZUMAB; BICALUTAMIDE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 7; DASATINIB; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; FLAVOPIRIDOL; FLUTAMIDE; GLUCOCORTICOID RECEPTOR; OBLIMERSEN; TAMOXIFEN; THALIDOMIDE; VORINOSTAT; WNT PROTEIN;

ARTICLE; COMPUTER MODEL; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE MAPPING; HISTOLOGY; LUNG CANCER; LUNG LARGE CELL CANCER; LUNG SMALL CELL CANCER; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; SEX DETERMINATION; SIGNAL TRANSDUCTION;

EID: 70449555464     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ba20cf     Document Type: Article

References (20)

1. The US National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Data Base, 1973-2004. Available at: http://seer.cancer.gov/2007. Accessed March 30, 2009.
2. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the Lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002;124:285-292.
3. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-1197.
4. Noda K, Nishiwaki Y, Kawahara M, et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346: 85-91.
5. Veronesi G, Morandi U, Alloisio M, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006;53:111-115.
6. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population based study in Denmark. Lung Cancer 2002;37: 127-135.
7. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068.
8. Jones MH, Virtanen C, Honjoh D, et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004;363:775-781.
9. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39-50.
10. GSE6044 record. Available at: http://www.ncbi.nlm.nih.gov/sites/entrez. Accessed March 30, 2009.
11. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264.
12. Moriya Y, Iyoda A, Kasai Y, et al. Prediction of lymph node metastasis by gene expression profiling in patients with primary resected lung cancer. Lung Cancer 2009;64:86-91.
13. Ingenuity Pathway Analysis. Available at:. Accessed March 30, 2009.
14. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 1995;57:289-300.
15. Jimeno A, Li J, Messersmith WA, et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-5510.
16. Mross K, Frost A, Steinbild S, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-5517.
17. Available at: Clinicaltrials.gov. Accessed June 1, 2009.
18. NCCN Practice Guidelines v. 2.2009. Available at:. Accessed June 1, 2009.
19. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res 1995;15:503-505.
20. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006;24: 492-496. (Pubitemid 44576401)